Clinical Now with Featured Trials from the American Diabetes Association's 69th Annual Scientific Sessions!

Besides a price drop to $9.99, the latest version (1.4) of the Clinical Trials iPhone app brings a new feature to the Bookmarks page: a section called Featured Trials.

In this section we'll be highlighting the major late-breaking trials in endocrinology coming out of the ADA's 69th Scientific Sessions. This will make it easier for our users to reference the details of these trials while they're in New Orleans, or off-site from anywhere in the world where they have a connection.

So far we have Featured Trials that coincide with ADA late-breaking abstracts being presented on:

  • Abstract 6-LB. DURATION-2: Exenatide once-weekly compared to sitagliptin or pioglitazone (NCT00637273)
  • Abstract 7-LB. INCB13739 plus metformin vs metformin alone in type 2 diabetes (NCT00698230)
  • Abstract 12-LB. EGO: Dose titration of LY2189265 in overweight patients with diabetes (NCT00632805)
  • Abstract 13-LB. The first farnesoid-X receptor agonist (INT-747) study in diabetes (NCT00501592)
  • Abstract 15-LB. Pioglitazone and long-term progression of atherosclerosis in IGT (ACT NOW: NCT00220961)
  • Abstract 96-LB. BLOOM: Behavioral modification and lorcaserin for overweight and obesity management (NCT00395135)
  • Abstract 97-LB. Mifepristone to prevent risperidone-induced weight gain in healthy male volunteers (NCT00698022)
  • Be sure to check your Featured Trials listing as we add more to the page and keep up with the ADA's 69th Annual Scientific Sessions!

    Download Clinical from the App Store, or see our Featured Trials demo video below (flash required).